期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 12, 期 10, 页码 1289-1300出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.10.1289
关键词
antiprotease therapy; endoproteolysis; proprotein convertases; proteases; protease inhibitors; proteolytic processing; therapeutic targets
资金
- Canadian Institute for Health Research, the Natural Sciences and Engineering Council of Canada
- Heart and Stroke Ontario, Canada Stroke Network and the Strauss Foundation.
Background: Limited endoproteolysis of precursor proteins is a common mechanism of production of functional proteins and peptides. In the secretory pathway of eukaryotic cells, this endoproteolysis is principally mediated by a family of calcium-dependent serine proteases, generically known as proprotein convertases. Altered expression of these enzymes in experimental animal models and in humans has been associated with numerous pathologies, including infertility, developmental defects, metabolic dysfunctions, cancer, cardiovascular diseases and infectious diseases. Objective: To review experimental evidence of the therapeutic potential of proprotein convertase inhibitors or silencers. Conclusions: Several potent inhibitors have been developed and successfully tested. Their therapeutic use must await further improvements in potency, selectivity, cellular delivery and tissue targeting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据